2. 筋萎縮性側索硬化症 Amyotrophic lateral sclerosis Clinical trials / Disease details

臨床試験数 : 645 / 薬物数 : 589 - (DrugBank : 163) / 標的遺伝子数 : 150 - 標的パスウェイ数 : 225

4 trials found

diseases per page:

Showing 1 to 4 of 4 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03293069 (ClinicalTrials.gov)	January 1, 2019	21/9/2017	Conservative Iron Chelation as a Disease-modifying Strategy in Amyotrophic Lateral Sclerosis	Conservative Iron Chelation as a Disease-modifying Strategy in Amyotrophic Lateral Sclerosis: Multic ...	Amyotrophic Lateral Sclerosis	Drug: Deferiprone;Drug: Placebo Oral Tablet	University Hospital, Lille	Ministry of Health, France	Active, not recruiting	18 Years	75 Years	All	372	Phase 2/Phase 3	France
2	EUCTR2017-003763-35-FR (EUCTR)	17/05/2018	05/03/2018	conservative iron chelation by deferiprone for amyotrophic lateral sclerosis	Conservative Iron Chelation by Deferiproneas a disease-modifying Strategy for Amyotrophic Lateral Sc ...	De novo Amyotrophic Lateral Sclerosis patients;Therapeutic area: Diseases [C] - Nervous System Disea ...	Product Name: Deferiprone DR INN or Proposed INN: DEFERIPRONE	centre hospitalier universitaire de Lille	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	240	Phase 3	France
3	NCT02164253 (ClinicalTrials.gov)	September 2013	20/5/2014	Focal Accumulation of Iron in Cerebral Regions in Early ALS (Amyotrophic Lateral Sclerosis) Patients ...	Feasibility and Safety Pilot Therapeutic Study of the Iron Chelator Deferipronein Amyotrophic Latera ...	ALS (Amyotrophic Lateral Sclerosis);Iron Overload	Drug: Deferiprone	University Hospital, Lille	ApoPharma	Completed	18 Years	85 Years	All	23	Phase 2	France
4	NCT02880033 (ClinicalTrials.gov)	February 2011	3/8/2016	Oxidative Stress and Apoptosis of Energy Metabolism by Deferiprone From the Circulating Lymphocytes	Modulation of Oxidative Stress and Apoptosis of Energy Metabolism by DeferiproneFrom the Circulating ...	Parkinson's Disease;Amyotrophic Lateral Sclerosis;Oxidative Stress;Iron Overload	Drug: deferiprone;Drug: placebo	University Hospital, Lille	NULL	Completed	18 Years	80 Years	All	90	N/A	France

First Previous1Next Last